Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04018820
Other study ID # 2017-005
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2017
Est. completion date June 22, 2018

Study information

Verified date December 2021
Source Université de Sherbrooke
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Eleven men with myotonic dystrophy type 1 (DM1) underwent a 12-week lower-limb strength training program. The training program consisted of 3 series of 6 to 8 maximal repetitions of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. Training sessions were closely supervised and took place twice a week. It is hypothesised that the training program will induce muscular hypertrophy despite the genetic defect. The training program should also have positive effects on function. The participants were evaluated at baseline, week 6, week 12, month 6 and month 9 to see the effects of the training program and if these effects are maintained over time.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date June 22, 2018
Est. primary completion date June 22, 2018
Accepts healthy volunteers No
Gender Male
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria: - DM1 diagnosis must be confirmed by genetic analysis; - Male gender, aged between 30 and 65 years old; - Be able to walk without assistance; - Consent of the neurologist must be given to participate in this study; - Must reside in the Saguenay-Lac-St-Jean region; - Subjects must be able to give their consent freely and voluntarily. Exclusion Criteria: - Patients with any other form of muscular dystrophy are excluded; - Any contraindication for strenuous exercise or muscle biopsy.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Training program
12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.

Locations

Country Name City State
Canada Groupe de recherche interdisciplinaire sur les maladies neuromusculaires Saguenay Quebec

Sponsors (2)

Lead Sponsor Collaborator
Élise Duchesne Fondation du Grand défi Pierre Lavoie

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in maximal isometric muscle strength of the knee extensors Changes in maximal isometric muscle strength of the knee extensors measured by quantified muscle testing using a handheld dynamometer At baseline, week 6, week 12, month 6 and month 9
Secondary Changes in maximal isometric muscle strength of the knee flexors Changes in maximal isometric muscle strength of the knee flexors measured by quantified muscle testing using a handheld dynamometer At baseline and week 12
Secondary Changes in maximal isometric muscle strength of the hip flexors Changes in maximal isometric muscle strength of the hip flexors measured by quantified muscle testing using a handheld dynamometer At baseline and week 12
Secondary Changes in maximal isometric muscle strength of the hip extensors Changes in maximal isometric muscle strength of the hip extensors measured by quantified muscle testing using a handheld dynamometer At baseline and week 12
Secondary Changes in maximal isometric muscle strength of the ankle dorsiflexors Changes in maximal isometric muscle strength of the ankle dorsiflexors measured by quantified muscle testing using a handheld dynamometer At baseline and week 12
Secondary Changes in 1-repetition maximum strength of the leg extension exercise Changes in 1-repetition maximum strength of the leg extension exercise At baseline, week 6 and week 12
Secondary Changes in 1-repetition maximum strength of the leg press exercise Changes in 1-repetition maximum strength of the leg press exercise At baseline, week 6 and week 12
Secondary Changes in 1-repetition maximum strength of the hip abduction exercise Changes in 1-repetition maximum strength of the hip abduction exercise At baseline, week 6 and week 12
Secondary Changes in 1-repetition maximum strength of the squat exercise Changes in 1-repetition maximum strength of the squat exercise At baseline, week 6 and week 12
Secondary Changes in comfortable walking speed in the 10-meter walk test Changes in comfortable walking speed in the 10-meter walk test At baseline, week 6, week 12, month 6 and month 9
Secondary Changes in maximal walking speed in the 10-meter walk test Changes in maximal walking speed in the 10-meter walk test At baseline, week 6, week 12, month 6 and month 9
Secondary Changes in the number of repetitions in the 30-seconds sit-to-stand test Changes in the number of repetitions in the 30-seconds sit-to-stand test At baseline, week 6, week 12, month 6 and month 9
Secondary Changes in the score of the lower extremity functional scale Changes in the score of the lower extremity functional scale (LEFS). The LEFS is an 80-point questionnaire with 20 items scored from 0 to 4. A score of 80 means no disfunction while a score of 0 means maximal disfunction. At baseline, week 12, month 6 and month 9
Secondary Changes in the score of the myotonic dystrophy health index Changes in the score of the myotonic dystrophy health index (MDHI). The MDHI is a 114-item questionnaire scored from 0 to 100, where 0 means no disability and 100 means maximal disability. At baseline, week 6, week 12, month 6 and month 9
Secondary Changes in the score of the Fatigue and Daytime Sleepiness Scale Changes in the score of the Fatigue and Daytime Sleepiness Scale (FDSS). The FDSS is a 12-item questionnaire where all questions are scored from 0 to 2. A higher score means more daytime sleepiness and fatigue. At baseline, week 6, week 12, month 6 and month 9
Secondary Changes in the Marin apathy scale Changes in the Marin apathy scale. The Marin apathy scale is scored by the clinician where he interviews the subject and then scores an 18-item list on a scale of 1 to 4. A high score means more apathy. At baseline, week 12, month 6 and month 9
Secondary Changes in the Well-Being Manifestations Measure Scale Changes in the Well-Being Manifestations Measure Scale (WBMMS). The WBMMS is a 25-item questionnaire where each question is scored on a scale from 1 to 5. A high score means high well-being. At baseline, week 6, week 12 and month 6
Secondary Changes in the Hospital Anxiety and Depression Scale Changes in the Hospital Anxiety and Depression Scale (HADS). The HADS is a 14-item questionnaire with a scale from 0 to 3 for each item. A high score means high depression and anxiety. At baseline, week 6, week 12 and month 6
Secondary Changes in muscle biopsy of the vastus lateralis: muscle fiber typing Changes in muscle biopsy of the vastus lateralis: muscle fiber typing At baseline and week 12
Secondary Changes in muscle biopsy of the vastus lateralis: muscle fiber size Changes in muscle biopsy of the vastus lateralis: muscle fiber size (smallest diameter of the fiber) At baseline and week 12
Secondary Changes in muscle biopsy of the vastus lateralis: muscle proteomics Changes in muscle biopsy of the vastus lateralis: muscle proteomics (protein expression) At baseline and week 12
Secondary Changes in muscle biopsy of the vastus lateralis: muscle transcriptomics Changes in muscle biopsy of the vastus lateralis: muscle transcriptomics (RNA expression analysis) At baseline and week 12
Secondary Changes in muscle biopsy of the vastus lateralis: mitochondrial function Changes in muscle biopsy of the vastus lateralis: mitochondrial function. Analysis of mitochondrial markers and enzymes At baseline and week 12
Secondary Changes in muscle biopsy of the vastus lateralis: Nuclear foci Changes in muscle biopsy of the vastus lateralis: Nuclear foci (changes in accumulation of nuclear foci) At baseline and week 12
See also
  Status Clinical Trial Phase
Recruiting NCT02880735 - Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy N/A
Recruiting NCT06378216 - Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]
Active, not recruiting NCT06089018 - Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy
Completed NCT05662150 - Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1 N/A
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT05027269 - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2
Completed NCT04712422 - Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
Recruiting NCT05006924 - Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1
Recruiting NCT04656210 - Myotonic Dystrophy - Vascular and Cognition
Completed NCT04634682 - Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 N/A
Withdrawn NCT06270186 - Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach N/A
Recruiting NCT06411288 - Global Study of Del-desiran for the Treatment of DM1 Phase 3
Recruiting NCT06300307 - Study of ATX-01 in Participants With DM1 Phase 1/Phase 2
Completed NCT02729597 - Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study N/A
Recruiting NCT06138743 - Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Phase 1
Not yet recruiting NCT05532813 - Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease) Phase 3
Active, not recruiting NCT04886518 - Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Phase 2
Completed NCT05036447 - Myotonic Dystrophy Type 1 and Resistance Exercise N/A
Recruiting NCT03424460 - Venous Thromboembolism in Myotonic Dystrophy Type 1 N/A
Recruiting NCT05865483 - Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)